30.01.2024 – 11:00
Sanofi-Aventis Deutschland GmbH
Frankfurt/Main (ots)
The number of people affected by neurodermatitis has risen to 3.8 million in recent years.[1] But research has not stood still, so modern treatment options are now available that can be used long-term. Dermatologist and neurodermatitis expert Prof. Dr. explains what modern therapies are and how those affected become “informed patients.” Claudia Traidl-Hoffmann.
“It feels as if small ants with very pointed legs were crawling over the affected areas. There is also a burning and tightness because the skin is so dry that it tears with every movement,” says Sophie, describing the feeling during a neurodermatitis treatment. Push. And she is not alone in that. In recent years, the number of people affected by neurodermatitis has increased, now to over 3.8 million in Germany.[1] Neurodermatitis is a chronic inflammatory skin disease. It is accompanied by severe itching and inflamed, sometimes bleeding areas of skin and progresses in episodes.[2] “It’s getting worse, but it’s also getting better. And there is help,” says Sophie. After a long search, she found a modern, long-term therapy that suits her.
Long-term solutions for those affected by neurodermatitis
For many sufferers, neurodermatitis represents a major burden in everyday life and is more than “just a skin disease”. It is triggered, among other things, by an imbalance in the immune system and disruptions in the skin barrier contribute to the ongoing inflammatory processes.[3,4] “Today we can treat the systemic disease neurodermatitis!” says Prof. Dr. Traidl-Hoffmann – alluding to the results of research in recent years. From her point of view, the treatment of neurodermatitis has revolutionized in the last five years: “Today we have solutions for patients with neurodermatitis!” says the dermatologist and allergist. This refers to the development of modern systemic therapies that can be used in the long term for moderately to severely affected patients. These modern therapy options include biologics and JAK inhibitors.
Knowledge is power – the relevance of neurodermatitis education
In order to deal well with a complex disease such as neurodermatitis, it is particularly important to be comprehensively informed. Sanofi’s website leben-mit-neurodermitis.info can provide support here. It offers a lot of information about the disease for those affected, their relatives and those interested. Prof. Traidl-Hoffmann emphasizes: “The informed patient is the one who can live better with the disease,” and thus underlines the value that knowledge can have for those affected by neurodermatitis. In this way, an individual therapy concept can be developed together with dermatologists. But exchanging ideas with other affected people can also be helpful. This is where the community on the Instagram channel @ leben_mit_neurodermitis.info comes in.
The full video with interesting information about neurodermatitis and tips from expert Prof. Traidl-Hoffmann is available on YouTube.
About Sanofi
We are an innovative global healthcare company with a single purpose: exploring the wonders of science to improve people’s lives. Our team works in more than 100 countries to transform medical practice and make the impossible possible. We provide life-saving vaccines and treatments that have the potential to improve lives to millions of people worldwide. We place sustainability and social responsibility at the center of our actions.
Sanofi is listed on the EURONEXT: SAN and NASDAQ: SNY stock exchanges.
credentials
[1] (last accessed 10/2023)
[2] Werfel et al. S2k AWMF guideline neurodermatitis. 2015:013-027 with amendment to systemic therapy 2020:013-027.
[3] Leung DYM et al. J Clin Invest 2004; 113:651-657
[4] Werfel T et al. Dtsch Ärztebl Int 2014; 111:509-20
MAT-DE-2304790 v1.0 (11/2023)
Press contact:
Christiane Klein
Tel.: +49 (0)69 305 80784
[email protected]
Original content from: Sanofi-Aventis Deutschland GmbH, transmitted by news aktuell